The proportion of dasatinib reimbursed by medical insurance

Dasatinib (Dasatinib) is a second-generation BCR-ABL tyrosine kinase inhibitor (TKI) developed, mainly used to treat chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). This drug effectively blocks the proliferation and survival signals of leukemia cells by precisely inhibiting abnormal tyrosine kinase activity. Therefore, it is regarded as one of the important treatment options for patients with imatinib resistance or intolerance.

In China, dasatinib has been included in the national medical insurance directory, which has greatly reduced the financial pressure on patients. According to the policy announced by the National Medical Insurance Bureau, the medical insurance reimbursement ratio of dasatinib varies slightly depending on regional policies, and is generally between 50% and 70%. In most provinces, patients diagnosed with chronic myelogenous leukemia or Ph+ acute lymphoblastic leukemia can enjoy drug reimbursement if they meet the medical insurance drug indications. Some regions have further expanded the scope of use after secondary negotiations, allowing more eligible patients to benefit.

From the perspective of drug prices, the current common specifications on the domestic market are: 50mg×60 tablets and 20mg×60 tablets. The price of the 50mg specification is about RMB 10,000. If calculated based on standard dosage, the cost of treatment for a month is about 10,000 to 12,000 yuan. After medical insurance is reimbursed, the patient's out-of-pocket portion usually ranges from three to five thousand yuan. The specific amount is affected by the type of medical insurance, reimbursement ratio and overall payment limit. It is worth noting that some areas have “secondary reimbursement” or “relief funds” for major diseases, and the actual out-of-pocket amount may be further reduced.

Compared with the international market, the post-negotiation price of China's medical insurance is already at a relatively low level. The monthly cost of dasatinib in the U.S. and European markets is generally over several thousand dollars, while generic versions in Laos and other regions are more economical, but they still need to be carefully evaluated in terms of efficacy consistency and registration compliance.

Reference materials:https://go.drugbank.com/drugs/DB01254